MT 501
Alternative Names: MT-501Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Mirador Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 11 Dec 2024 Phase-I clinical trials in Unspecified (In volunteers) in USA (PO) (NCT06762457)